Informação sobre produto
Belinostat acid is an inorganic compound that has been clinically studied for its potential use in cancer treatment. Belinostat acid is a histone deacetylase inhibitor, which means it prevents the removal of acetyl groups from histones, resulting in gene activation and increased transcription. In vitro studies have shown that belinostat acid can be used to treat cancers by inducing homologous recombination repair and inhibiting cell proliferation. Clinical trials are currently underway to examine the safety and efficacy of this drug as a treatment for solid tumors. The terminal half-life of belinostat acid is about 1 hour, with metabolites being excreted primarily through urine.
Belinostat Acid has been found to inhibit HDACs and other DNA-modifying enzymes such as HATs. It also inhibits the phosphorylation of H3K9, which may play a role in tumorigenesis.
The pharmacokinetics of Belinostat
Propriedades químicas
Consulta técnica sobre: 3D-RJB32387 Belinostat acid
Se desejar solicitar um orçamento ou fazer uma encomenda, por favor, adicione os produtos ao seu carrinho e depois solicite um orçamento ou encomenda a partir do carrinho. É mais rápido, mais barato e poderá beneficiar-se dos descontos e outras vantagens disponíveis.
